Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose ‐reduced 3‐weekly docetaxel for metastatic castration‐resistant prostate cancer

ConclusionsLD docetaxel for mCRPC did not mitigate the risk of FN or ETC due to toxicity. Dose reduction may result in poorer PSA response and survival.

Source: Asia-Pacific Journal of Clinical Oncology - January 10, 2018 Category: Cancer & Oncology Authors: Anis A. Hamid, Kaspar Willson, Andrew D. Vincent, Babak Tamjid, Margaret Lee, Alice Bergin, Chun Gan, Ainsley Campbell, Josephine Stewart, Carmel Pezaro, Ben Tran, Andrew J. Weickhardt Tags: ORIGINAL ARTICLE Source Type: research